Abstract Body

Despite antiretroviral therapy (ART), people with HIV (PWH) are at higher risk for infection-related and lung cancers and lower risk for prostate cancer than the general population. The inflammatory pathways that may contribute to these risks are incompletely characterized.

Using a case-cohort design, a random sample of all CNICS participants with available plasma during ?6 months of ART-mediated viral suppression was selected. Among eligible participants, all those subsequently diagnosed with anal, non-Hodgkin’s Lymphoma (NHL), lung, or prostate cancer were also sampled. The relationship between 6 plasma biomarkers, log10-transformed and normalized to the cohort interquartile range (IQR), and each incident cancer was assessed by multivariate Cox proportional hazards modeling with inverse probability sampling weights based on cohort versus event status, adjusting for age, sex, and smoking history.

Of an eligible cohort of 9,340, we sampled a random sub-cohort of 968 participants and 36 anal, 37 lung, and 36 prostate cancer cases and 19 non-Hodgkin’s Lymphoma cases, occurring at a median of 4 (IQR 2-6) years following the plasma sample. The sub-cohort had a median age of 47, 83% were men, 29% had a history of smoking, and the median current and nadir CD4 were 573 and 245, respectively. After adjustment, every IQR increase in sCD14 and CMV IgG titer was associated with a 2.9- and 1.7-fold increased hazard of anal cancer (P=0.001, P=0.003, Figure). Every IQR increase in IL-18 (a biomarker of IL-1? signaling) and sCD14 was associated with a 1.4- and 2.9-fold increased hazard of lung cancer (P=0.008, P=0.04). Each IQR increase in sCD163 was associated with a 5.2-fold increased hazard of NHL (P=0.02). Finally, each IQR increase in CMV IgG titer was associated with a 1.7-fold increased hazard or prostate cancer (P<0.001), while LPS binding protein (LBP) was associated with a reduced risk (aHR=0.61, P=0.003).

Distinct patterns of inflammation predict different types of cancer in treated HIV, suggesting that interventions targeting discrete inflammatory pathways in this setting are likely to affect risks of some cancers more than others. Nevertheless, CMV IgG titer tended to predict most cancers, potentially suggesting a broader impact of CMV or related exposures on cancer risk in this setting. LBP’s association with decreased prostate cancer risk may reflect previously reported LPS- and/or inflammation-mediated suppression of testosterone levels.